Company intelligence / Profile preview
Polpharma Biologics
Gdańsk, Polandpolpharmabiologics.com ↗
- Ownership
- Private
- Employees
- ~1299
- Development stage
- Commercial
01
Overview
Polpharma Biologics has achieved regulatory approvals in both the US and Europe for Tyruko®—the first natalizumab biosimilar for relapsing forms of multiple sclerosis. Its vedolizumab biosimilar candidate has demonstrated PK/PD comparability to Entyvio® in clinical studies. The pipeline also includes preclinical programs targeting oncology and immunology indications.
- Therapeutic areas
- GastroenterologyOncologyImmunologyNeurology
- Modalities
- BiosimilarsMonoclonal antibodies (mAbs)Biological products
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Sandoz – commercialization partner for Tyruko® in Europe and the US.
Beyond the preview
Go deeper on Polpharma Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Polpharma Biologics.